Sfoglia per AUTORE
PARIS L
Collezione AOU Città della Salute di Torino

  

Items : 10

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients. in European journal of haematology / Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19.

2025
AOU Città della Salute di Torino
AOU Novara

Quaresima M; Barbieri E; D'Arrigo G; Reddiconto G; Tripepi G; Morè S; Sica A; Mele G; Falcone AP; Mancuso K; Cangialosi C; Farina G; Vincelli ID; Paris L; Mina R; Fazio F; Bruzzese A; Vigna E; Della Pepa R; Mele A; Musso M; Palmieri S; Zamagni E; Conticello C; Bolli N; Pettine L; Petrucci MT; De Magistris C; Lotti F; et alii...

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. in Blood / Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.

2024
AOU Città della Salute di Torino

Paris L; Zambello R; Mancuso K; Gamberi B; Palmas AD; Gozzetti A; Cellini C; Ballanti S; Velluti C; Vincelli ID; Ronconi S; Pavone V; Grasso M; Ledda A; Oliva S; Corradini P; Morè S; Belotti A; Rota-Scalabrini D; Bertuglia G; D'Agostino M; Petrucci MT; Bruno B; Musto P; Gay F;

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. in Haematologica / Haematologica. 2023 Mar 1;108(3):833-842. doi: 10.3324/haematol.2022.281342.

2023
AOU Città della Salute di Torino

Mangiacavalli S; Cartia CS; Galli M; Pezzatti S; Belotti A; Fazio F; Mina R; Marcatti M; Cafro A; Zambello R; Paris L; Barilà G; Olivares C; Pompa A; Mazza R; Farina F; Soldarini M; Benvenuti P; Pagani G; Palumbo M; Masoni V; Ferretti VV; Klersy C; Arcaini L; Petrucci MT;

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F;

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino

Grasso M; Zamagni E; Fioritoni F; Ballanti S; Cea M; Pescosta N; Pavone V; Ronconi S; Vincelli ID; Oddolo D; Capra A; Bertamini L; Cellini C; Gozzetti A; De Rosa L; Giuliani N; Aquino S; de Fabritiis P; Gamberi B; Palmas A; Rota-Scalabrini D; Paris L; Musto P; Mina R; Belotti A; Boccadoro M; Gay F;

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6.

2022
AOU Alessandria
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Belotti A; Tacchetti P; Fazio F; Zambello R; Luppi M; Liberati AM; Palmieri S; Annibali O; Monaco F; Galieni P; Pisani F; Capra A; Gilestro M; Curci P; Pascarella A; Tosi P; De Sabbata G; Pietrantuono G; Gentile M; Ledda A; Paris L; Morè S; Corradini P; Rota-Scalabrini D; Oliva S; Bertamini L; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. in Haematologica / Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.

2020
ASL Torino 4
AOU Città della Salute di Torino

Boccadoro M; Larocca A; Falco P; Hájek R; Palumbo A; Marasca R; Cellini C; Petrucci MT; Tosi P; Gentile M; Baldini L; Santoro A; Aquino S; Poggiu M; Pavone V; Gazzera G; De Rosa L; Grasso M; Rota-Scalabrini D; Pezzatti S; Spada S; Ballanti S; Pescosta N; Paris L; D'Agostino M; Bringhen S;

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. in Haematologica / Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27.

2020
AOU Città della Salute di Torino

Palumbo A; De Paoli L; Romano A; Zambello R; Falcone AP; Giuliani N; Paris L; Fraticelli V; Amico V; Musto P; Bernardini A; Cangiolosi C; Innao V; Oddolo D; Benevolo G; Spada S; Evangelista A; Patriarca F; Ledda A; Liberati AM; Offidani M; Mina R; Larocca A; Montefusco V; Hájek R; Boccadoro M; Bringhen S;

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). in Haematologica / Haematologica. 2015 Feb;100(2):284-92. doi: 10.3324/haematol.2014.113399.

2015
AOU Città della Salute di Torino

Caira M; Candoni A; Verga L; Busca A; Delia M; Nosari A; Caramatti C; Castagnola C; Cattaneo C; Fanci R; Chierichini A; Melillo L; Mitra ME; Picardi M; Potenza L; Salutari P; Vianelli N; Facchini L; Cesarini M; De Paolis MR; Di Blasi R; Farina F; Venditti A; Ferrari A; Garzia M; Gasbarrino C; Invernizzi R; Lessi F; Manna A; et alii...